Join the Community

Join the Directory

Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease

Trial Information

Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease

Only patients requiring treatment (B-symptoms, lymphoma progression > 50% within an
observation period of 6 months or less, organ compression by lymphoma or bulky disease as
defined by lesions above 5 cm on one axis) may enter the study.

- No prior chemotherapy, immunotherapy, or irradiation. Furthermore, when receiving
therapy as part of this "Zevalin® first line in follicular lymphoma" trial and up to
six months after therapy has ended, patients may not participate in another clinical
trial. If patients receive consolidation therapy with Rituximab, the six months
period is counted from the end of the consolidation therapy.

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.